Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
September 10, 2025Neuro-OncologyOpen Access

M6a Rna Methylation as a Therapeutic Target in High Grade Glioma

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMasar RadhiJRJonathan RowlinsonLWLauryn Walker

Discussion

Loading...

Member takes

Overview

Investigating m6A RNA methylation's role in glioma progression and its impact on temozolomide sensitivity.

Key Points

  • Inhibition of METTL3 enhances the sensitivity of high grade glioma cells to temozolomide.
  • Knockdown of m6A effectors alters expression of transcription factors linked to tumorigenesis.
  • High levels of m6A modifications were observed in glioma cells, implicating RNA methylation in cancer progression.
  • m6A RNA methylation presents a promising target for new treatment strategies in high grade glioma.

Cite This Study

Radhi et al. (2025) studied this question.

synapsesocial.com/papers/68c23abeb210217d64781486https://doi.org/10.1093/neuonc/noaf185.001
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1EXPLORING THE GLIOMA M6A RNA EPITRANSCRIPTOME WITH DIRECT RNA SEQUENCING2025
  2. 2DYSREGULATION OF M6A RNA METHYLATION READERS AND ANTI-READERS, R-LOOPS AND THE DNA DAMAGE RESPONSE IN PAEDIATRIC HIGH-GRADE GLIOMAS2025
  3. 3N 6 -methyladenosine promotes temozolomide resistance through mRNA stabilization in glioblastoma cells2025
  4. 4Abstract P75: THE ROLE OF SETD2 IN THE MOLECULAR ONCOGENESIS OF GLIOMA THROUGH m6A RNA MODIFICATION2025
  5. 5METTL3-mediated m 6 A modification of DNMT1 enhances ovarian cancer progression2025